Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy.

Ranea-Robles P, Launay N, Ruiz M, Calingasan NY, Dumont M, Naudí A, Portero-Otín M, Pamplona R, Ferrer I, Beal MF, Fourcade S, Pujol A.

EMBO Mol Med. 2018 Aug;10(8). pii: e8604. doi: 10.15252/emmm.201708604.

2.

Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.

Tapias V, Jainuddin S, Ahuja M, Stack C, Elipenahli C, Vignisse J, Gerges M, Starkova N, Xu H, Starkov AA, Bettendorff L, Hushpulian DM, Smirnova NA, Gazaryan IG, Kaidery NA, Wakade S, Calingasan NY, Thomas B, Gibson GE, Dumont M, Beal MF.

Hum Mol Genet. 2018 Aug 15;27(16):2874-2892. doi: 10.1093/hmg/ddy201.

3.

Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease.

Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, Compadre CM, Goellner JJ, O'Brien CA, Fahmi T, Basnakian AG, Calingasan NY, Klessner JL, Beal FM, Peters OM, Metterville J, Brown RH Jr, Ling KKY, Rigo F, Ozdinler PH, Kiaei M.

Hum Mol Genet. 2017 Feb 15;26(4):686-701. doi: 10.1093/hmg/ddw429.

4.

Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.

Chandra A, Sharma A, Calingasan NY, White JM, Shurubor Y, Yang XW, Beal MF, Johri A.

Hum Mol Genet. 2016 Jun 1;25(11):2269-2282. Epub 2016 Mar 22.

5.

Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.

Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M.

Hum Mol Genet. 2016 Jan 15;25(2):317-27. doi: 10.1093/hmg/ddv477. Epub 2015 Nov 24.

6.

Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.

Morató L, Ruiz M, Boada J, Calingasan NY, Galino J, Guilera C, Jové M, Naudí A, Ferrer I, Pamplona R, Serrano M, Portero-Otín M, Beal MF, Fourcade S, Pujol A.

Cell Death Differ. 2015 Nov;22(11):1742-53. doi: 10.1038/cdd.2015.20. Epub 2015 Mar 27.

7.

PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Launay N, Gerges M, Starkova N, Starkov AA, Calingasan NY, Tampellini D, Pujol A, Beal MF.

FASEB J. 2014 Apr;28(4):1745-55. doi: 10.1096/fj.13-236331. Epub 2014 Jan 7.

8.

Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy.

Morató L, Galino J, Ruiz M, Calingasan NY, Starkov AA, Dumont M, Naudí A, Martínez JJ, Aubourg P, Portero-Otín M, Pamplona R, Galea E, Beal MF, Ferrer I, Fourcade S, Pujol A.

Brain. 2013 Aug;136(Pt 8):2432-43. doi: 10.1093/brain/awt143. Epub 2013 Jun 22.

9.

Nitration of Hsp90 induces cell death.

Franco MC, Ye Y, Refakis CA, Feldman JL, Stokes AL, Basso M, Melero Fernández de Mera RM, Sparrow NA, Calingasan NY, Kiaei M, Rhoads TW, Ma TC, Grumet M, Barnes S, Beal MF, Beckman JS, Mehl R, Estévez AG.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1102-11. doi: 10.1073/pnas.1215177110. Epub 2013 Mar 4.

10.

Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.

Yao J, Ho D, Calingasan NY, Pipalia NH, Lin MT, Beal MF.

J Exp Med. 2012 Dec 17;209(13):2501-13. doi: 10.1084/jem.20121239. Epub 2012 Dec 3.

11.

Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, Chan RB, Di Paolo G, Pujol A, Beal MF.

Hum Mol Genet. 2012 Dec 1;21(23):5091-105. doi: 10.1093/hmg/dds355. Epub 2012 Aug 24.

12.

Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease.

Gollamudi S, Johri A, Calingasan NY, Yang L, Elemento O, Beal MF.

PLoS One. 2012;7(5):e36191. doi: 10.1371/journal.pone.0036191. Epub 2012 May 1.

13.

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.

Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, Chandra A, Beal MF.

Hum Mol Genet. 2012 Mar 1;21(5):1124-37. doi: 10.1093/hmg/ddr541. Epub 2011 Nov 17.

14.

Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease.

Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF.

J Alzheimers Dis. 2011;27(1):211-23. doi: 10.3233/JAD-2011-110209.

15.

Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease.

Thomas B, Banerjee R, Starkova NN, Zhang SF, Calingasan NY, Yang L, Wille E, Lorenzo BJ, Ho DJ, Beal MF, Starkov A.

Antioxid Redox Signal. 2012 May 1;16(9):855-68. doi: 10.1089/ars.2010.3849. Epub 2011 Jun 16.

16.

Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis.

Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF, Kiaei M.

Free Radic Biol Med. 2011 Jul 1;51(1):88-96. doi: 10.1016/j.freeradbiomed.2011.03.027. Epub 2011 Mar 30.

17.

Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease.

Dumont M, Stack C, Elipenhali C, Calingasan NY, Wille E, Beal MF.

Neurosci Lett. 2011 Apr 4;492(3):150-4. doi: 10.1016/j.neulet.2011.01.077. Epub 2011 Feb 12.

18.

Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease.

Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF.

Exp Neurol. 2010 Sep;225(1):74-84. doi: 10.1016/j.expneurol.2010.05.006. Epub 2010 Jun 1.

PMID:
20561979
19.

Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Chaturvedi RK, Calingasan NY, Yang L, Hennessey T, Johri A, Beal MF.

Hum Mol Genet. 2010 Aug 15;19(16):3190-205. doi: 10.1093/hmg/ddq229. Epub 2010 Jun 7.

20.

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF.

Free Radic Biol Med. 2010 Jul 15;49(2):147-58. doi: 10.1016/j.freeradbiomed.2010.03.017. Epub 2010 Mar 23.

21.

N-iminoethyl-L-lysine improves memory and reduces amyloid pathology in a transgenic mouse model of amyloid deposition.

Dumont M, Wille E, Calingasan NY, Nathan C, Flint Beal M, Lin MT.

Neurochem Int. 2010 Jan;56(2):345-51. doi: 10.1016/j.neuint.2009.11.006. Epub 2009 Nov 13.

PMID:
19914323
22.

Promethazine protects against 3-nitropropionic acid-induced neurotoxicity.

Cleren C, Calingasan NY, Starkov A, Jacquard C, Chen J, Brouillet E, Beal MF.

Neurochem Int. 2010 Jan;56(2):208-12. doi: 10.1016/j.neuint.2009.10.006. Epub 2009 Oct 21.

23.

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, Stewart C, Hensley K, Beal MF, Kiaei M.

Exp Neurol. 2009 Nov;220(1):191-7. doi: 10.1016/j.expneurol.2009.08.028. Epub 2009 Sep 4.

24.

Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins.

Yang L, Shi Q, Ho DJ, Starkov AA, Wille EJ, Xu H, Chen HL, Zhang S, Stack CM, Calingasan NY, Gibson GE, Beal MF.

Neurobiol Dis. 2009 Nov;36(2):320-30. doi: 10.1016/j.nbd.2009.07.023. Epub 2009 Aug 4.

25.

Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition.

Dumont M, Ho DJ, Calingasan NY, Xu H, Gibson G, Beal MF.

Free Radic Biol Med. 2009 Oct 1;47(7):1019-27. doi: 10.1016/j.freeradbiomed.2009.07.008. Epub 2009 Jul 22.

26.

Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF.

PLoS One. 2009 Jun 1;4(6):e5757. doi: 10.1371/journal.pone.0005757.

27.

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF.

J Neurochem. 2009 Jun;109(5):1427-39. doi: 10.1111/j.1471-4159.2009.06074.x. Epub 2009 Mar 28.

28.

Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease.

Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT.

FASEB J. 2009 Aug;23(8):2459-66. doi: 10.1096/fj.09-132928. Epub 2009 Apr 3.

29.

Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF.

Antioxid Redox Signal. 2009 Sep;11(9):2095-104. doi: 10.1089/ARS.2009.2445.

30.

Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease.

Dumont M, Wille E, Calingasan NY, Tampellini D, Williams C, Gouras GK, Liby K, Sporn M, Nathan C, Flint Beal M, Lin MT.

J Neurochem. 2009 Apr;109(2):502-12. doi: 10.1111/j.1471-4159.2009.05970.x. Epub 2009 Feb 7. Erratum in: J Neurochem. 2009 May;109(4):1192.. Nathan, Carl [added].

31.

Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases.

Calingasan NY, Ho DJ, Wille EJ, Campagna MV, Ruan J, Dumont M, Yang L, Shi Q, Gibson GE, Beal MF.

Neuroscience. 2008 Jun 2;153(4):986-96. doi: 10.1016/j.neuroscience.2008.02.071. Epub 2008 Mar 18.

32.

Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.

Yang L, Calingasan NY, Lorenzo BJ, Beal MF.

Exp Neurol. 2008 May;211(1):311-4. doi: 10.1016/j.expneurol.2007.02.010. Epub 2007 Feb 27.

33.

Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.

Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF.

J Neurochem. 2008 Mar;104(6):1613-21. Epub 2007 Oct 31.

34.

The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis.

Petri S, Calingasan NY, Alsaied OA, Wille E, Kiaei M, Friedman JE, Baranova O, Chavez JC, Beal MF.

J Neurochem. 2007 Aug;102(3):991-1000.

35.

Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis.

Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, Heissig B, Rafii S, Lorenzl S, Beal MF.

Exp Neurol. 2007 May;205(1):74-81. Epub 2007 Feb 12.

PMID:
17362932
36.

MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.

Thomas B, von Coelln R, Mandir AS, Trinkaus DB, Farah MH, Leong Lim K, Calingasan NY, Flint Beal M, Dawson VL, Dawson TM.

Neurobiol Dis. 2007 May;26(2):312-22. Epub 2007 Jan 25.

37.

Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice.

Petri S, Kiaei M, Wille E, Calingasan NY, Flint Beal M.

J Neurol Sci. 2006 Dec 21;251(1-2):44-9. Epub 2006 Oct 17.

PMID:
17049562
38.

Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis.

Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF.

Neurodegener Dis. 2005;2(5):246-54.

PMID:
16909005
39.

Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis.

Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF.

J Neurochem. 2006 Aug;98(4):1141-8.

40.

Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF.

J Neurosci. 2006 Mar 1;26(9):2467-73.

41.

Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.

Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF.

Neurobiol Dis. 2006 Apr;22(1):40-9. Epub 2005 Nov 11.

PMID:
16289867
42.

Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

Cleren C, Starkov AA, Calingasan NY, Lorenzo BJ, Chen J, Beal MF.

Neurobiol Dis. 2005 Dec;20(3):701-8. Epub 2005 Aug 26.

PMID:
16126396
43.

Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.

Cleren C, Calingasan NY, Chen J, Beal MF.

J Neurochem. 2005 Aug;94(4):995-1004.

44.

Manganese porphyrin given at symptom onset markedly extends survival of ALS mice.

Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF.

Ann Neurol. 2005 Aug;58(2):258-65.

PMID:
16049935
45.

Alterations of striatal neurons in benign hereditary chorea.

Kleiner-Fisman G, Calingasan NY, Putt M, Chen J, Beal MF, Lang AE.

Mov Disord. 2005 Oct;20(10):1353-7.

PMID:
15986422
46.

Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.

Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF.

Neuromolecular Med. 2004;6(2-3):87-92.

PMID:
15970626
47.

CD40L deletion delays neuronal death in a model of neurodegeneration due to mild impairment of oxidative metabolism.

Ke ZJ, Calingasan NY, Karuppagounder SS, DeGiorgio LA, Volpe BT, Gibson GE.

J Neuroimmunol. 2005 Jul;164(1-2):85-92.

PMID:
15904977
48.

CD40-CD40L interactions promote neuronal death in a model of neurodegeneration due to mild impairment of oxidative metabolism.

Ke ZJ, Calingasan NY, DeGiorgio LA, Volpe BT, Gibson GE.

Neurochem Int. 2005 Aug;47(3):204-15.

PMID:
15885854
49.

Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients.

Calingasan NY, Chen J, Kiaei M, Beal MF.

Neurobiol Dis. 2005 Jun-Jul;19(1-2):340-7.

PMID:
15837590
50.

Supplemental Content

Loading ...
Support Center